6Moghimi S M,Hunter A C,Murray J C,et al.Long-circulating and target-specific nanoparticles:theory to practice[J].Pharmacol Rev,2001,53(2):283.
7Yoo H S,Lee K H,Park T G,et al.In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates[J].J Controlled Release,2000,68(3):419-431.
8Gulyaev A E,Gelperina S E,Skidan I N,et al.SkandSignificant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles[J].Pharm Res,1999,16(10):1564-1569.
9Nagaich S,Khopade J A,Jain N K,et al.Lipid grafts of egg-box complex:a new supramolecular biovector for 5-fluorouracil delivery[J].Pharm Acta Helv,1999,73(5):227-236.
10Tian X,Groves M J.Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles[J].J Pharm Pharmacol,1999,1(2):151-157.
4Schwarz C, Mehnert W. Solid liquid nanoparticles (SLN) for controlled drug delivery Ⅱ . Drug incorporation and physicochemical characterization[J]. J Microencapsulation, 1999,16(2) :205-213.
5Song CX, Labhasetwar V, Murohy H, et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery[ J ]. J Control Rel, 1997,43 : 197-212.
6Hincal A. Atilla, Kas, H. Suheyla. Recent advances in nanoparticles and nanospheres[C]. Biomed Sci. Technol. [ Proc. Int.Syrmp, 4th, Meeting Date], 1997,31-39.
7Song C X，J Control Release，1997年，43卷，197页
8Wu D C，第四军医大学学报，1999年，20卷，2期，125页
9Pierre Lehn, Sylvie Fabrega, Noufissa Oudrhiri, et al. Gene delivery systems: Bridging the gap between recombinant viruses and artificial vectors[J]. Adv. Drug Delve. Rev,1998,30:5-11.
10Truong Le, Walsh, Scott M, et al. Gene transfer by DNA-gelatin nanospheres[J]. Arch Biochem Biophys, 1999,361(1):47-56.
